Teva Pharmaceutical Industries Limited (NYSE:TEVA) was downgraded by equities researchers at UBS AG from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Thursday, August 3rd, The Fly reports.
A number of other research firms have also recently issued reports on TEVA. Credit Suisse Group set a $39.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Oppenheimer Holdings, Inc. lowered shares of Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating and set a $41.00 price objective for the company. in a research note on Thursday, August 3rd. Mizuho reaffirmed a “hold” rating and issued a $30.00 price objective on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 2nd. Jefferies Group LLC reissued a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a report on Tuesday, July 25th. Finally, Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price objective on the stock in a research report on Monday, July 24th. Three analysts have rated the stock with a sell rating, twenty have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and an average target price of $36.73.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 2.23% during midday trading on Thursday, reaching $17.10. The company had a trading volume of 12,988,997 shares. The company’s market capitalization is $17.37 billion. The stock’s 50 day moving average is $28.36 and its 200 day moving average is $31.20. Teva Pharmaceutical Industries Limited has a one year low of $16.81 and a one year high of $53.96.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by $0.07. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The firm’s quarterly revenue was up 12.9% on a year-over-year basis. During the same quarter last year, the company posted $1.25 earnings per share. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Rating Lowered by UBS AG” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://stocknewstimes.com/2017/08/17/teva-pharmaceutical-industries-limited-nyseteva-cut-to-market-perform-at-ubs-ag-updated.html.
Large investors have recently made changes to their positions in the stock. Guggenheim Capital LLC increased its stake in shares of Teva Pharmaceutical Industries Limited by 1.1% in the fourth quarter. Guggenheim Capital LLC now owns 40,276 shares of the company’s stock valued at $1,460,000 after buying an additional 446 shares in the last quarter. Teachers Advisors LLC purchased a new stake in shares of Teva Pharmaceutical Industries Limited during the fourth quarter valued at $21,946,000. Macquarie Group Ltd. increased its stake in shares of Teva Pharmaceutical Industries Limited by 3.3% in the fourth quarter. Macquarie Group Ltd. now owns 919,973 shares of the company’s stock valued at $33,349,000 after buying an additional 29,770 shares in the last quarter. Park National Corp OH increased its stake in shares of Teva Pharmaceutical Industries Limited by 7.5% in the first quarter. Park National Corp OH now owns 18,114 shares of the company’s stock valued at $582,000 after buying an additional 1,265 shares in the last quarter. Finally, Chevy Chase Trust Holdings Inc. increased its stake in shares of Teva Pharmaceutical Industries Limited by 3.4% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 6,273 shares of the company’s stock valued at $201,000 after buying an additional 207 shares in the last quarter. 56.04% of the stock is currently owned by institutional investors and hedge funds.
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.
